

Bruno Scheller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1023969/publications.pdf>

Version: 2024-02-01

103
papers

7,557
citations

81743

39
h-index

53109

85
g-index

107
all docs

107
docs citations

107
times ranked

4289
citing authors

#	ARTICLE	IF	CITATIONS
1	Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg. <i>New England Journal of Medicine</i> , 2008, 358, 689-699.	13.9	732
2	Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter. <i>New England Journal of Medicine</i> , 2006, 355, 2113-2124.	13.9	675
3	Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis. <i>Circulation</i> , 2009, 119, 2986-2994.	1.6	451
4	CD14 ⁺⁺ CD16 ⁺ Monocytes Independently Predict Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1512-1520.	1.2	449
5	Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis. <i>Circulation</i> , 2004, 110, 810-814.	1.6	394
6	Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. <i>Lancet</i> , The, 2018, 392, 849-856.	6.3	263
7	Angioplasty of Femoral-Popliteal Arteries With Drug-Coated Balloons. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 102-108.	1.1	230
8	Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2003, 42, 634-641.	1.2	228
9	Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. <i>Clinical Research in Cardiology</i> , 2008, 97, 773-781.	1.5	227
10	Drug-Coated Balloons for Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1391-1402.	1.1	218
11	Long-Term Follow-Up After Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon Catheter. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 323-330.	1.1	197
12	SeQuent Please World Wide Registry. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1733-1738.	1.2	186
13	Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. <i>Clinical Research in Cardiology</i> , 2010, 99, 165-174.	1.5	165
14	Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. <i>Clinical Research in Cardiology</i> , 2013, 102, 785-797.	1.5	157
15	Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2321-2330.	1.2	154
16	Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. <i>Clinical Research in Cardiology</i> , 2015, 104, 217-225.	1.5	143
17	Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1415-1420.	1.2	137
18	Do Pharmacokinetics Explain Persistent Restenosis Inhibition by a Single Dose of Paclitaxel?. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 392-400.	1.4	123

#	ARTICLE	IF	CITATIONS
19	Neointima Inhibition: Comparison of Effectiveness of Non- σ Stent-based Local Drug Delivery and a Drug-eluting Stent in Porcine Coronary Arteries. <i>Radiology</i> , 2006, 240, 411-418.	3.6	111
20	Contrast media as carriers for local drug delivery Successful inhibition of neointimal proliferation in the porcine coronary stent model. <i>European Heart Journal</i> , 2003, 24, 1462-1467.	1.0	109
21	How to use the drug-eluting balloon: recommendations by the German consensus group. <i>EuroIntervention</i> , 2011, 7, K125-K128.	1.4	109
22	Dose Response to Paclitaxel-Coated Balloon Catheters in the Porcine Coronary Overstretch and Stent Implantation Model. <i>Investigative Radiology</i> , 2011, 46, 255-263.	3.5	106
23	Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. <i>Lancet</i> , The, 2020, 396, 1504-1510.	6.3	96
24	Drug-eluting balloon: Very short-term exposure and overlapping. <i>Thrombosis and Haemostasis</i> , 2009, 101, 201-206.	1.8	94
25	Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. <i>Clinical Research in Cardiology</i> , 2009, 98, 325-330.	1.5	90
26	Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 558-566.	1.1	82
27	Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months?. <i>EuroIntervention</i> , 2013, 9, 620-628.	1.4	79
28	Effect of Aspiration Thrombectomy on Microvascular Obstruction in NSTEMI Patients. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1117-1124.	1.2	75
29	Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. <i>European Heart Journal</i> , 2016, 37, 1096-1103.	1.0	73
30	Drug eluting balloons as stand alone procedure for coronary bifurcational lesions: results of the randomized multicenter PEPCAD-BIF trial. <i>Clinical Research in Cardiology</i> , 2016, 105, 613-621.	1.5	71
31	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1017-1028.	1.2	70
32	Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. <i>Clinical Research in Cardiology</i> , 2012, 101, 469-476.	1.5	68
33	Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. <i>EuroIntervention</i> , 2020, 15, 1527-1533.	1.4	60
34	Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study. <i>EuroIntervention</i> , 2015, 11, 926-934.	1.4	57
35	Novel Sirolimus- σ Coated Balloon Catheter. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003543.	1.4	55
36	Reduction of Stenosis Due to Intimal Hyperplasia After Stent Supported Angioplasty of Peripheral Arteries by Local Administration of Paclitaxel in Swine. <i>Investigative Radiology</i> , 2007, 42, 579-585.	3.5	51

#	ARTICLE	IF	CITATIONS
37	Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19. <i>Clinical Research in Cardiology</i> , 2020, 109, 1500-1506.	1.5	50
38	Inhibition of Restenosis in Stented Porcine Coronary Arteries. <i>Investigative Radiology</i> , 2004, 39, 182-186.	3.5	45
39	Relationship Between Time to Invasive Assessment and Clinical Outcomes of Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 166-174.	1.1	39
40	State of the art: balloon catheter technologies " drug-coated balloon. <i>EuroIntervention</i> , 2017, 13, 680-695.	1.4	39
41	Prevention of restenosis: is angioplasty the answer?. <i>Heart</i> , 2007, 93, 539-541.	1.2	36
42	Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells. <i>EuroIntervention</i> , 2011, 7, K32-K42.	1.4	36
43	Paclitaxel-coated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study. <i>EuroIntervention</i> , 2012, 8, 450-455.	1.4	33
44	A novel drug-coated scoring balloon for the treatment of coronary in-stent restenosis: Results from the multi-center randomized controlled <scp>PATENT</scp> first in human trial. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 51-59.	0.7	32
45	Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. <i>Cardiovascular Diabetology</i> , 2020, 19, 215.	2.7	30
46	Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting - A feasibility and safety study. <i>International Journal of Cardiology</i> , 2016, 225, 262-267.	0.8	29
47	Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry. <i>Atherosclerosis</i> , 2021, 332, 48-54.	0.4	28
48	COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction. <i>Heart</i> , 2022, 108, 458-466.	1.2	28
49	Treatment of Coronary De Novo Lesions by a Sirolimus- or Paclitaxel-Coated Balloon. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 770-779.	1.1	27
50	Stent Coverage and Neointimal Proliferation in Bare Metal Stents Postdilated With a Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 760-767.	1.4	26
51	Drug-eluting balloon: very short-term exposure and overlapping. <i>Thrombosis and Haemostasis</i> , 2009, 101, 201-6.	1.8	25
52	One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry. <i>Clinical Research in Cardiology</i> , 2020, 109, 845-856.	1.5	24
53	Long-term effects on vascular healing of bare metal stents delivered via paclitaxel-coated balloons in the porcine model of restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 603-610.	0.7	23
54	Inhibition of neointimal hyperplasia in porcine coronary arteries utilizing a novel paclitaxel-coated scoring balloon catheter. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 1089-1098.	0.7	23

#	ARTICLE	IF	CITATIONS
55	Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: Comparison with a drug eluting stent and a bare metal stent. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 323-331.	0.7	22
56	Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1789-1798.	1.1	22
57	Plasma levels of the oxyphytosterol 7 β -hydroxycampesterol are associated with cardiovascular events. <i>Atherosclerosis</i> , 2018, 279, 17-22.	0.4	20
58	Drug Distribution and Basic Pharmacology of Paclitaxel/Resveratrol-Coated Balloon Catheters. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1599-1610.	0.9	19
59	Acute Cardiac Tolerance of Current Contrast Media and the New Taxane Protaxel Using Iopromide as Carrier During Porcine Coronary Angiography and Stenting. <i>Investigative Radiology</i> , 2002, 37, 29-34.	3.5	18
60	Treatment of a coronary bifurcation lesion with drug-coated balloons: lumen enlargement and plaque modification after 6 months. <i>Clinical Research in Cardiology</i> , 2013, 102, 469-472.	1.5	18
61	Drug-coated balloon versus drug-eluting stent in small coronary artery lesions: angiographic analysis from the BASKET-SMALL 2 trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1114-1124.	1.5	18
62	Inhibition of neointimal proliferation after bare metal stent implantation with low-pressure drug delivery using a paclitaxel-coated balloon in porcine coronary arteries. <i>Clinical Research in Cardiology</i> , 2012, 101, 385-391.	1.5	17
63	Results From the International Drug Coated Balloon Registry for the Treatment of Bifurcations. Can a Bifurcation Be Treated Without Stents?. <i>Journal of Interventional Cardiology</i> , 2016, 29, 348-356.	0.5	17
64	Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 101161CIRCINTERVENTIONS121011569.	1.4	17
65	Coronary artery treatment with a urea-based paclitaxel-coated balloon: the European-wide FALCON all-comers DCB Registry (FALCON Registry). <i>EuroIntervention</i> , 2019, 15, e382-e388.	1.4	16
66	Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011325.	1.4	15
67	Evaluation of occurring complications after flow diverter treatment of elastase-induced aneurysm in rabbits using micro-CT and MRI at 9.4 μ T. <i>Neuroradiology</i> , 2016, 58, 987-996.	1.1	13
68	Thrombus aspiration in non-ST-elevation myocardial infarction – 12-month clinical outcome of the randomised TATORT-NSTEMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 10-17.	0.4	13
69	Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2. <i>Clinical Cardiology</i> , 2018, 41, 569-575.	0.7	13
70	Short- and long-term effects of a novel paclitaxel coated stent in the porcine coronary model. <i>Clinical Research in Cardiology</i> , 2008, 97, 118-123.	1.5	11
71	Paclitaxel-coated balloons: a safe alternative to drug-eluting stents for coronary in-stent restenosis. <i>European Heart Journal</i> , 2020, 41, 3729-3731.	1.0	11
72	Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis. <i>Clinical Research in Cardiology</i> , 2014, 103, 21-27.	1.5	10

#	ARTICLE	IF	CITATIONS
73	Valvular heart disease in patients with chronic kidney disease. <i>Herz</i> , 2021, 46, 228-233.	0.4	10
74	A novel constrained, paclitaxel-coated angioplasty balloon catheter. <i>EuroIntervention</i> , 2017, 12, 2140-2147.	1.4	10
75	Management of recurrent in-stent restenosis: onion skin full metal jacket?. <i>EuroIntervention</i> , 2013, 9, 781-785.	1.4	10
76	Best way to revascularize patients with main stem and three vessel lesions: patients should undergo PCI!. <i>Clinical Research in Cardiology</i> , 2010, 99, 531-539.	1.5	9
77	Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 806-815.	1.5	8
78	Drug-Coated Balloon Treatment as Default Strategy for DES-ISR. <i>Journal of the American College of Cardiology</i> , 2016, 67, 346-347.	1.2	6
79	Causes of death after treatment of small coronary artery disease with paclitaxel-coated balloons. <i>Clinical Research in Cardiology</i> , 2021, 110, 307-311.	1.5	6
80	Long-term outcome after thrombus aspiration in non-ST-elevation myocardial infarction: results from the TATORT-NSTEMI trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1223-1231.	1.5	5
81	Drug-Coated Balloons – The New Gold Standard for Treatment of Coronary In-Stent Restenosis?. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 257-259.	0.3	4
82	Late lumen enlargement after treatment of de-novo lesions with drug coated balloon catheters – Glagov effect or plaque regression?. <i>International Journal of Cardiology</i> , 2021, 329, 79-81.	0.8	4
83	Efficacy and safety of a magnesium stearate paclitaxel coated balloon catheter in the porcine coronary model. <i>International Journal of Cardiology</i> , 2021, 331, 46-56.	0.8	4
84	Drug Coated Balloons in Acute Coronary Syndromes - Opportunities and Limitations. <i>Current Vascular Pharmacology</i> , 2012, 10, 472-475.	0.8	4
85	Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111469.	2.5	3
86	Preclinical Evaluation of the Temporary Drug-Coated Spur Stent System in Porcine Peripheral Arteries. <i>Journal of Endovascular Therapy</i> , 2021, 28, 938-949.	0.8	3
87	Clinical outcome after interventions with paclitaxel-coated balloons: a PCR statement. <i>EuroIntervention</i> , 2020, 15, 1225-1227.	1.4	3
88	A novel paclitaxel coated balloon with increased drug transfer for treatment of complex vascular lesions. <i>PLoS ONE</i> , 2021, 16, e0259106.	1.1	3
89	Novel, vessel anatomy adjusting drug-coated balloon – Preclinical evaluation in peripheral porcine arteries. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 319-328.	0.7	2
90	Editorial: Rotational Atherectomy Followed by Drug-Coated Balloons in Calcified Coronary De Novo Lesions – An Alternative to Stent Implantation?. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 654-656.	0.3	2

#	ARTICLE	IF	CITATIONS
91	Reduction of Outflow Tract Obstruction After PCI to Proximal LAD in a Patient With HOCM. JACC: Case Reports, 2020, 2, 384-388.	0.3	2
92	Response to Letter Regarding Article, "Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis" Circulation, 2010, 121, .	1.6	1
93	Drug-coated balloons in the treatment of small vessel disease: Table 1. Heart, 2014, 100, 274-275.	1.2	1
94	Learning from mistakes: The case of drug-coated balloons. International Journal of Cardiology, 2015, 182, 224-226.	0.8	1
95	Myocardial infarction in a patient with single coronary artery - rare but real. Journal of Cardiology Cases, 2021, 23, 246-249.	0.2	1
96	New technologies in percutaneous coronary interventions: drug-coated balloons. EuroIntervention, 2011, 7, K7-K7.	1.4	1
97	Renin-Angiotensin System inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID Pandemic. Diabetes Epidemiology and Management, 2021, 4, 100022.	0.4	1
98	Drug-coated balloon angioplasty for in-stent restenosis " a question of the right device or the right patient selection and technique?. EuroIntervention, 2020, 16, e276-e278.	1.4	1
99	Drug-Coated Balloons for Coronary De Novo Disease " What Should Optimal Lesion Preparation Look Like?. Cardiovascular Revascularization Medicine, 2022, 35, 96-97.	0.3	1
100	The promise of leaving nothing behind " And how to manage its failure. Cardiovascular Revascularization Medicine, 2017, 18, 473-474.	0.3	0
101	Drug-coated balloons for patients with increased risk of bleeding. Lancet, The, 2019, 394, 190-192.	6.3	0
102	Treatment of in-Stent Restenosis - What is Important in the Interest of the Patient?. Cardiovascular Revascularization Medicine, 2019, 20, 544-545.	0.3	0
103	Off-the-shelf barrier for emergency intubation in the cardiac catheterization laboratory during the coronavirus disease 2019 (COVID-19) pandemic. Clinical Research in Cardiology, 2020, 109, 1507-1509.	1.5	0